Saturday 17 October 2026
Export BCAB’s income statement to Excel — free account
BioAtla, Inc.
BCAB Healthcare Biotechnology
BioAtla, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 81.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4,233.3%, EPS grew 101.7% and free cash flow grew 97.0%, each against the same quarter a year earlier.
1.36
0.06
+4.62%
Follow BCAB
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | 4 | 3 | — | — | — | — |
P/S ratio |
— | 953.36 | 953.36 | 668.31 | 1,149.85 | — | — | 2.52 | 2.93 |
Altman Z-Score |
— | — | — | 5.02 | 8.13 | — | — | (16.13) | (70.06) |
Altman Z″-Score (non-manufacturers) |
— | (45.34) | (88.66) | 9.85 | 6.01 | — | — | (34.72) | (164.82) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
P/Operating CF |
— | (162.22) | (162.22) | (20.47) | (32.38) | — | — | (1.71) | (4.22) |
P/B ratio |
— | 0.00 | 0.00 | 1.37 | 3.22 | — | — | 2.01 | 0.00 |
Price to Tangible BV |
— | 0.00 | 0.00 | 1.37 | 3.22 | — | — | 2.01 | 0.00 |
EV/Sales |
— | 973.27 | 973.27 | 136.33 | 752.24 | — | — | (0.87) | 3.22 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.14 | 0.00 |
EV/Operating CF |
— | (80.09) | (80.09) | (1.61) | (7.13) | — | — | 0.14 | (0.76) |
EV/FCF |
— | (76.04) | (76.04) | (1.58) | (7.03) | — | — | 0.14 | (0.76) |
Quick Ratio |
— | 1.18 | 0.14 | 7.40 | 12.36 | 9.32 | 3.93 | 3.37 | 0.32 |
Current Ratio |
— | 1.38 | 0.17 | 7.46 | 12.48 | 9.53 | 4.11 | 3.52 | 0.37 |
Net Debt/EBITDA |
— | (0.15) | (0.53) | 8.18 | 2.58 | 2.02 | 0.87 | 0.67 | 0.12 |
Debt/Assets |
0.00% | 90.16% | 194.09% | 0.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | (0.53) | (0.32) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 1.28 | 0.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.06 |
Operating CF/Net income |
— | 1.25 | 0.34 | 1.01 | 0.65 | 0.85 | 0.84 | 1.03 | 0.81 |
Capex/Depreciation |
— | 0.00 | (1.75) | (0.59) | (0.69) | (0.22) | (0.08) | 0.00 | 0.00 |
Interest Coverage |
— | (48.76) | (17.34) | (21.67) | (32,146.67) | (65.62) | — | — | — |
| — | 21.41% | 21.77% | (112.27%) | (45.34%) | (54.44%) | (98.37%) | (164.30%) | 543.76% | |
| — | (338.57%) | (221.24%) | (28.20%) | (38.21%) | (44.35%) | (71.49%) | (81.10%) | (179.95%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (383.50%) | 163.84% | (16.87%) | (41.27%) | (53.23%) | (137.69%) | (186.72%) | 432.28% |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 240.06% | 498.44% | 4,646.39% | 23,309.60% | 0.00% | 0.00% | 573.59% | 2,178.65% |
Selling, General and Administrative Expense of Revenue |
— | 118.15% | 145.17% | 2,469.70% | 15,366.40% | 0.00% | 0.00% | 198.62% | 886.60% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 704.43% | 10,046.80% | 0.00% | 0.00% | 81.10% | 271.70% |
Graham Net Nets |
— | 0.02 | 0.02 | 0.72 | 0.30 | — | — | 0.46 | (1.26) |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 186.94 |
Earnings Yield |
— | (0.48%) | (0.48%) | (12.52%) | (14.11%) | — | — | (243.65%) | (177.82%) |
Free Cash Flow Yield |
— | (1.34%) | (1.34%) | (12.88%) | (9.31%) | — | — | (250.92%) | (144.55%) |
Revenue per Share |
— | 0.32 | 4.76 | 2.54 | 0.36 | 0.00 | 0.00 | 11.32 | 1.70 |
Operating CF per Share |
— | (1.05) | (8.83) | (215.50) | (90.01) | (116.15) | (108.85) | (74.05) | (40.97) |
Capex per Share |
— | 0.00 | (1.38) | (3.50) | (1.34) | (0.34) | (0.10) | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (1.05) | (10.21) | (219.00) | (91.35) | (116.49) | (108.95) | (74.05) | (40.97) |
Cash per Share |
— | 0.32 | 3.39 | 1,415.21 | 354.43 | 276.82 | 116.65 | 50.48 | 6.05 |
Shareholders Equity per Share |
— | (0.85) | (51.29) | 1,245.40 | 305.01 | 231.65 | 73.96 | 14.68 | (30.76) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.85) | (51.29) | 1,245.40 | 305.01 | 231.65 | 73.96 | 14.68 | (30.76) |
Free Cash Flow |
— | (35.32) | (11.15) | (36.92) | (63.14) | (90.68) | (104.11) | (71.94) | (48.20) |
Working Capital |
— | 3.47 | (22.21) | 208.42 | 227.48 | 197.30 | 88.06 | 36.69 | (13.91) |
Capital Expenditures |
— | (0.99) | (1.51) | (0.59) | (0.92) | (0.26) | (0.10) | — | — |
Net Current Asset Value |
— | (32.42) | (60.84) | 205.72 | 203.69 | 175.03 | 67.42 | 13.08 | (42.00) |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.13 | 0.00 |
Capex to Sales |
— | 0.00 | 0.29 | 1.38 | 3.70 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.20 | 0.18 | 0.25 | 0.36 | 0.44 | 0.76 | 1.36 | 3.11 |
Cash ROIC |
— | 1,357.30% | 32.63% | (8.22%) | (13.85%) | (22.91%) | (57.16%) | (113.62%) | 165.81% |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Payables |
— | 3.55 | 6.97 | 12.02 | 15.25 | 20.02 | 24.17 | 20.21 | 15.03 |
Average Assets |
— | 8.32 | 12.99 | 127.14 | 249.68 | 240.08 | 172.70 | 86.04 | 33.13 |
Average Common Equity |
— | (131.56) | (131.96) | 31.93 | 210.40 | 195.58 | 125.51 | 42.47 | (10.96) |
Columns are period end dates